GlassScriptPhysician profile
Lyndsey Slape
NPI 1245836592
$6,396.73
in general payments reported to CMS, 2019-2025
24 companies · $857 in 2025
The $857 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.96 · 2022: $879 · 2023: $1,999 · 2024: $2,638 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,150 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,150.07 |
| Education | $342.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,092.00 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $1,085.32 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $618.90 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $423.51 | 2023-2024 | Vtama |
| Lilly USA, LLC | $380.71 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $362.67 | 2022-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $358.96 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $313.91 | 2023-2025 | |
| Ucb, INC. | $279.37 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $272.37 | 2023-2025 | Dupixent, Libtayo |
| Abbvie INC. | $255.22 | 2023-2025 | |
| Galderma Laboratories, L.P. | $213.58 | 2025 | Nemluvio |
| Janssen Biotech, INC. | $202.61 | 2023-2024 | Simponi, Simponi Aria, Stelara |
| Nalu Medical, INC. | $112.64 | 2024 | Nalu Neurostimulation System |
| Leo Pharma INC. | $102.50 | 2022-2023 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $72.11 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.05 | 2023-2025 | Spevigo, Cyltezo |
| Pfizer INC. | $37.75 | 2022-2023 | |
| Vertex Pharmaceuticals Incorporated | $31.69 | 2025 | |
| Journey Medical Corporation | $31.20 | 2023-2025 | |
| Organon LLC | $27.36 | 2025 | Vtama |
| Boston Scientific Corporation | $24.96 | 2021 | |
| Krystal Biotech INC | $14.18 | 2025 | Vyjuvek |
| Helsinn Therapeutics (U.S.), INC. | $14.16 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyndsey Slape listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.